TD Cowen analyst Yaron Werber has maintained their bullish stance on TERN stock, giving a Buy rating on February 9.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yaron Werber has given his Buy rating due to a combination of factors related to Terns Pharmaceuticals’ key program and recent data. He is taking over coverage from the prior analyst without altering the positive stance, reflecting continuity in the firm’s conviction about the company’s prospects.
Werber is especially encouraged by the early clinical performance of TERN-701 in chronic myeloid leukemia, which has led him to lift his long‑term revenue assumptions for this asset. The strengthened sales outlook, supported by initial results from the Phase 1/2 CARDINAL study, underpins his view that the stock offers attractive upside potential for investors at current levels.
In another report released on February 9, Leerink Partners also initiated coverage with a Buy rating on the stock with a $58.00 price target.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TERN in relation to earlier this year.